This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
Financier Worldwide Magazine featured CRA’s Dr. Gregory Bell as an Exceptional Expert in the Power Players report on International Arbitration.
Antimicrobial resistance (AMR) imposes a significant burden on patients facing both acute and chronic infections.
Join CRA and leading European payer experts for a 30-minute virtual webinar as we explore how growing competitive dynamics are reshaping the rare diseases...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
